Former Celgene shareholders sued Bristol Myers Squibb to recover $6.4 billion from the company. According to the plaintiff, Bristol Myers deliberately applied late to the FDA for approval of the cancer drug Breyanzi. This allowed Bristol Myers to avoid additional payments to shareholders of the recently acquired Celgene.